Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF), a UK-based biotech firm, announced today the signing of a Master Service Agreement (MSA) with CER Groupe, a private Belgian research organization. This agreement aims to enhance the companies’ long-term research and development collaboration, particularly in the field of gene therapy.
The MSA outlines a framework for the development, production, and characterization of Genflow’s gene therapy candidates. It also includes the implementation of a collaborative project management system designed to facilitate efficient execution and timely delivery of services that support Genflow’s objectives.
Dr. Eric Leire, CEO of Genflow, commented on the significance of the partnership, stating that the formalized collaboration with CER will allow for greater operational alignment and strategic agility, which is vital for the acceleration of Genflow’s pipeline.
Genflow Biosciences, established in 2020, focuses on pioneering gene therapies aimed at slowing the aging process to promote longer, healthier lives. The company’s lead compound, GF-1002, involves the delivery of a centenarian variant of the SIRT6 gene and has shown promising preclinical results. Genflow recently initiated a 12-month proof-of-concept clinical trial in March 2025 to evaluate their SIRT6-centenarian gene therapy in aged dogs. Additionally, they plan to conduct a clinical trial in 2025 to investigate the potential benefits of GF-1002 in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a common chronic liver disease currently lacking effective treatments.
CER Groupe has over 45 years of experience in supporting European life sciences innovation. It is a GLP-certified research center that provides high-quality integrated bioproduction and non-clinical services to help companies advance from concept to IND-enabling studies.
This collaboration is expected to combine the scientific expertise of both organizations to innovate and achieve meaningful scientific outcomes. The information regarding this partnership is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.